Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 494.03B | 485.35B | 456.05B | 414.88B | 261.10B | 193.78B |
Gross Profit | 195.23B | 188.56B | 162.58B | 125.53B | 84.23B | 41.34B |
EBITDA | 100.54B | 94.87B | 80.16B | 52.27B | 25.28B | 26.70B |
Net Income | 32.09B | 31.07B | 24.84B | 12.39B | -3.59B | -1.65B |
Balance Sheet | ||||||
Total Assets | 0.00 | 817.15B | 676.60B | 547.46B | 436.01B | 420.67B |
Cash, Cash Equivalents and Short-Term Investments | 118.61B | 118.61B | 68.62B | 61.47B | 44.78B | 26.47B |
Total Debt | 0.00 | 499.62B | 408.02B | 311.61B | 241.45B | 240.77B |
Total Liabilities | -158.45B | 658.70B | 558.46B | 439.50B | 350.11B | 329.37B |
Stockholders Equity | 158.45B | 122.32B | 90.05B | 85.52B | 73.04B | 78.62B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -15.20B | -73.92B | -54.28B | 23.36B | -18.17B |
Operating Cash Flow | 0.00 | 1.28B | -62.58B | -44.99B | 28.45B | -10.65B |
Investing Cash Flow | 0.00 | -57.58B | 11.35B | -29.35B | -19.17B | -9.91B |
Financing Cash Flow | 0.00 | 69.58B | 84.32B | 72.81B | -3.78B | 13.31B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | ₹789.98B | 24.62 | ― | 2.32% | 5.82% | 30.97% | |
68 Neutral | ₹183.89B | 61.52 | ― | 0.48% | -2.17% | 4.39% | |
64 Neutral | ₹196.45B | 75.37 | ― | ― | 15.67% | 40.44% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
63 Neutral | ₹564.60B | 100.68 | ― | 0.30% | 50.34% | -3.00% | |
62 Neutral | ₹593.31B | 57.44 | ― | 0.68% | -6.19% | 8.09% | |
61 Neutral | ₹43.11B | 30.31 | ― | 0.59% | 8.15% | 16.13% |
Ashok Leyland Limited has scheduled a conference call for analysts and investors on August 14, 2025, to discuss the financial results for the quarter ended June 30, 2025. The call will feature a management discussion on earnings performance followed by a Q&A session, providing insights into the company’s financial health and strategic direction.